Please login to the form below
aclidinium
This page shows the latest aclidinium news and features for those working in and with pharma, biotech and healthcare.
Circassia seeks shift to AIM after failing LSE criteria
The Oxford-based company is buying US commercial rights to AstraZeneca’s chronic obstructive pulmonary disease (COPD) medicine Tudorza (aclidinium bromide), a drug that the two companies have partnered since 2017. ... Duaklir (aclidinium/formoterol)
Latest news
-
Circassia exits allergy R&D after placebo effect strikes again
Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
-
GSK's triple COPD therapy tops Symbicort in phase III trial
These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer
-
GSK brings forward triple COPD therapy filing in US
GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto
-
Boehringer bags FDA approval for Spiriva-based combo
AstraZeneca is also bringing its aclidinium bromide/formoterol fumarate product -sold in Europe as Duaklir - through the latter stages of development.
-
GSK sees COPD future in triple therapy
Duaklir (formoterol fumarate and aclidinium bromide) jostling for market share.
More from news
Approximately 1 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Interview: Jorge Gallardo, Almirall
We now have five R&D projects about to start or already in phase III and we are intending to register another two projects in 2011: aclidinium bromide for chronic obstructive
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- GSK discontinues two feladilimab trials in head and neck cancer
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Moderna’s booster vaccine for South African variant demonstrates promising early results
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Live Webinar: Advancing Human Health Through Precise Measures of Movement, Cognition & Biometrics
- Live Webinar: How to Simplify Genetics & Raise Awareness Around Orphan Diseases
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
PMHub
Windrose Consulting Group
Founded in 2015, Windrose Consulting Group is a privately-held global strategy firm that partners with life science companies to maximize...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
